Scott W. Bagley
Scott W. Bagley has a total of 378 co-authors. Here are the top co-authors by number of shared publications:
- David A. Griffith
Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
12 shared publications Alan M. Mathiowetz
Pfizer Medicine Design, Cambridge, MA 02139, United States
6 shared publicationsDavid A. Price
Pfizer Worldwide Research, Development, and Medical, Cambridge, Massachusetts 02139, United States
6 shared publicationsAaron C. Smith
Pfizer Worldwide Research & Development , Eastern Point Road, Groton, Connecticut 06340, United States
5 shared publications- James A. Southers
Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
5 shared publications - Robert L. Dow
Pfizer Global Research and Development, Groton, CT 06340, USA
5 shared publications
Latest Publications
- 10 September 2026
- Published by Wiley in Chemistry – A European Journal
Enabling the Synthesis of the 4’‐Thioremdesivir Core
Nucleosides and nucleoside analogs represent a long established and highly important class of pharmaceutical agents, with numerous U.S. Food and Drug Administration (FDA)–approved examples spanning antiviral, anticancer, and immunological indications. Among these, 4′‐thionucleosides—wherein the endocyclic ribose oxygen is replaced by sulfur—have emerged as particularly attractive bioisosteric analogs, frequently exhibiting enhanced pharmacokinetic and pharmacodynamic properties. Despite decades of investigation into 4′‐thionucleosides, the literature overwhelmingly focuses on anomeric N‐linked derivatives, while reports describing C‐linked 4′‐thionucleosides remain remarkably scarce. In this study, we report the first successful synthesis of the parent 4′‐thionucleoside core of remdesivir. In contrast to the well‐established β‐selective deoxycyanation observed in the ribose series, substitution of oxygen with sulfur results in a pronounced reversal of anomeric selectivity, favoring the undesired α‐isomer. This intrinsic bias was overcome through the discovery and exploitation of an unprecedented bridged oxythioketal intermediate, enabling access to the β‐configured product. The relative and absolute stereochemistry was confirmed by single‐crystal x‐ray diffraction, correcting a recent misassignment in the literature. Computational and NMR reaction monitoring studies provide mechanistic insight into thioribose reactivity and establish a framework for controlling anomeric stereochemistry in C‐ linked 4′‐thionucleoside synthesis. These results establish a foundation for future C‐ linked 4′‐thionucleoside antiviral development.
- 10 September 2026
- Published by Wiley in Chemistry – A European Journal
Enabling the Synthesis of the 4’‐Thioremdesivir Core
Nucleosides and nucleoside analogs represent a long established and highly important class of pharmaceutical agents, with numerous U.S. Food and Drug Administration (FDA)–approved examples spanning antiviral, anticancer, and immunological indications. Among these, 4′‐thionucleosides—wherein the endocyclic ribose oxygen is replaced by sulfur—have emerged as particularly attractive bioisosteric analogs, frequently exhibiting enhanced pharmacokinetic and pharmacodynamic properties. Despite decades of investigation into 4′‐thionucleosides, the literature overwhelmingly focuses on anomeric N‐linked derivatives, while reports describing C‐linked 4′‐thionucleosides remain remarkably scarce. In this study, we report the first successful synthesis of the parent 4′‐thionucleoside core of remdesivir. In contrast to the well‐established β‐selective deoxycyanation observed in the ribose series, substitution of oxygen with sulfur results in a pronounced reversal of anomeric selectivity, favoring the undesired α‐isomer. This intrinsic bias was overcome through the discovery and exploitation of an unprecedented bridged oxythioketal intermediate, enabling access to the β‐configured product. The relative and absolute stereochemistry was confirmed by single‐crystal x‐ray diffraction, correcting a recent misassignment in the literature. Computational and NMR reaction monitoring studies provide mechanistic insight into thioribose reactivity and establish a framework for controlling anomeric stereochemistry in C‐ linked 4′‐thionucleoside synthesis. These results establish a foundation for future C‐ linked 4′‐thionucleoside antiviral development.
- Open Access
- 9 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis
Interleukin-2-inducible T cell kinase is expressed by T cells and amplifies T cell receptor-dependent signals. Interleukin-2-inducible T cell kinase deletion or inhibition reduces production of interleukin-4 and interleukin-13, key drivers of atopic dermatitis. Nerve growth factor signals via the receptor tropomyosin-related kinase A and may promote pruritus in atopic dermatitis lesions. Here we describe PF-07245303, a compound which potently inhibits interleukin-2-inducible T cell kinase and tropomyosin-related kinase family kinases capable of inhibiting T cell receptor-mediated cytokine production from CD4 and CD8 T cells and suppressing nerve growth factor-induced human basophil activation. In human skin explants, PF-07245303 demonstrates inhibition of tropomyosin-related kinase A phosphorylation, suppresses cytokine expression from T cell receptor-activated resident T cells and reverses the expression of atopic dermatitis associated genes. Topical application of PF-07245303 reduces proinflammatory and epidermal changes in a dermatitis model using female mice. By inhibiting both pathogenic inflammatory mechanisms, PF-07245303 may have therapeutic value for patients with atopic dermatitis.
- 9 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessDiscovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis
Interleukin-2-inducible T cell kinase is expressed by T cells and amplifies T cell receptor-dependent signals. Interleukin-2-inducible T cell kinase deletion or inhibition reduces production of interleukin-4 and interleukin-13, key drivers of atopic dermatitis. Nerve growth factor signals via the receptor tropomyosin-related kinase A and may promote pruritus in atopic dermatitis lesions. Here we describe PF-07245303, a compound which potently inhibits interleukin-2-inducible T cell kinase and tropomyosin-related kinase family kinases capable of inhibiting T cell receptor-mediated cytokine production from CD4 and CD8 T cells and suppressing nerve growth factor-induced human basophil activation. In human skin explants, PF-07245303 demonstrates inhibition of tropomyosin-related kinase A phosphorylation, suppresses cytokine expression from T cell receptor-activated resident T cells and reverses the expression of atopic dermatitis associated genes. Topical application of PF-07245303 reduces proinflammatory and epidermal changes in a dermatitis model using female mice. By inhibiting both pathogenic inflammatory mechanisms, PF-07245303 may have therapeutic value for patients with atopic dermatitis.
- 2 December 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (50) , 45841-45848
Annulative Skeletal Diversification of Pyrimidines to Expanded Heteroaromatic Space
Single-atom skeletal editing has recently emerged as a powerful strategy for the direct diversification of the heterocyclic cores of various compounds. Yet, methods that enable monocycle-to-bicycle transformations that involve core atom changes remain scarce. Herein, we report a two-step, one-pot protocol that converts pyrimidines into 7-azaindazoles and pyrazolo[1,5-a]pyrimidines, two privileged scaffolds in medicinal chemistry. Fine-tuning the reaction parameters enables chemodivergent control, allowing selective access to either framework, with the pyrimidine scope including pharmaceutical drug molecules. Moreover, the strategy has been extended to afford differently substituted pyrimidines, partially saturated fused skeletons, and quinoline derivatives. Access to this broad, expanded, heteroaromatic space underscores the potential for heterocyclic diversification using this approach.
- 2 December 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (50) , 45841-45848
Annulative Skeletal Diversification of Pyrimidines to Expanded Heteroaromatic Space
Single-atom skeletal editing has recently emerged as a powerful strategy for the direct diversification of the heterocyclic cores of various compounds. Yet, methods that enable monocycle-to-bicycle transformations that involve core atom changes remain scarce. Herein, we report a two-step, one-pot protocol that converts pyrimidines into 7-azaindazoles and pyrazolo[1,5-a]pyrimidines, two privileged scaffolds in medicinal chemistry. Fine-tuning the reaction parameters enables chemodivergent control, allowing selective access to either framework, with the pyrimidine scope including pharmaceutical drug molecules. Moreover, the strategy has been extended to afford differently substituted pyrimidines, partially saturated fused skeletons, and quinoline derivatives. Access to this broad, expanded, heteroaromatic space underscores the potential for heterocyclic diversification using this approach.
- Open Access
- 10 November 2025
- Published by Springer Nature in Nature Synthesis
- Vol. 5 (3) , 349-356
Oxygen migration into carbon–carbon single bonds by photochemical oxidation
The editing of organic molecules through single-atom modification is an enabling capability for medicinal chemistry. Although several examples of single-atom insertions into the carbon–carbon double bonds of unsaturated aromatic ring systems have been reported, heteroatom insertions into chemically inert carbon–carbon single bonds are comparatively rare. Here we report a photochemical strategy for the formal migration of oxygen atoms into carbon–carbon single bonds. This protocol is based on the ability of copper(II) salts to induce photochemical homolytic cleavage of carbon–carbon bonds adjacent to alcohols and to mediate oxidative coupling reactions of the resulting organoradical intermediates. Application of this method to cyclic alcohol substrates results in oxygen atom insertions into saturated carbocyclic rings, and its extension to linear alcohol substrates enables atomic permutation of hydroxymethyl functionalities into methyl ethers.
- 10 November 2025
- Published by Springer Nature in Nature Synthesis
- Vol. 5 (3) , 349-356
Open AccessOxygen migration into carbon–carbon single bonds by photochemical oxidation
The editing of organic molecules through single-atom modification is an enabling capability for medicinal chemistry. Although several examples of single-atom insertions into the carbon–carbon double bonds of unsaturated aromatic ring systems have been reported, heteroatom insertions into chemically inert carbon–carbon single bonds are comparatively rare. Here we report a photochemical strategy for the formal migration of oxygen atoms into carbon–carbon single bonds. This protocol is based on the ability of copper(II) salts to induce photochemical homolytic cleavage of carbon–carbon bonds adjacent to alcohols and to mediate oxidative coupling reactions of the resulting organoradical intermediates. Application of this method to cyclic alcohol substrates results in oxygen atom insertions into saturated carbocyclic rings, and its extension to linear alcohol substrates enables atomic permutation of hydroxymethyl functionalities into methyl ethers.
- 22 September 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (19) , 20689-20716
Discovery of PF-07054894, a Potent Squaramide-Based CCR6 Antagonist Displaying High CXCR2 Selectivity
The G protein-coupled receptor (GPCR) CCR6 mediates the migration of pathogenic immune cells to the site of inflammation in response to the chemokine CCL20. CCR6 is an attractive target for the treatment of chronic autoimmune disease as antagonism of the receptor is expected to block CCL20-mediated immune cell recruitment. High-throughput-screening identified a squaramide-based, allosteric antagonist of CCR6 that potently inhibited CCL20-mediated T cell chemotaxis, but it also inhibited CXCL1-mediated neutrophil chemotaxis through CXCR2 antagonism. Lead optimization achieved differentiation from CXCR2 through identification of a methyl substituent-dependent selectivity switch or “magic methyl for selectivity”. The mechanism for this effect is rooted in different antagonist-induced ligand–receptor behaviors, insurmountable for CCR6 and surmountable for CXCR2. Herein, we report the discovery and preclinical evaluation of the CCR6 antagonist PF-07054894 (18l) which has advanced to clinical trials as a first in class approach targeting the receptor.
- 22 September 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (19) , 20689-20716
Discovery of PF-07054894, a Potent Squaramide-Based CCR6 Antagonist Displaying High CXCR2 Selectivity
The G protein-coupled receptor (GPCR) CCR6 mediates the migration of pathogenic immune cells to the site of inflammation in response to the chemokine CCL20. CCR6 is an attractive target for the treatment of chronic autoimmune disease as antagonism of the receptor is expected to block CCL20-mediated immune cell recruitment. High-throughput-screening identified a squaramide-based, allosteric antagonist of CCR6 that potently inhibited CCL20-mediated T cell chemotaxis, but it also inhibited CXCL1-mediated neutrophil chemotaxis through CXCR2 antagonism. Lead optimization achieved differentiation from CXCR2 through identification of a methyl substituent-dependent selectivity switch or “magic methyl for selectivity”. The mechanism for this effect is rooted in different antagonist-induced ligand–receptor behaviors, insurmountable for CCR6 and surmountable for CXCR2. Herein, we report the discovery and preclinical evaluation of the CCR6 antagonist PF-07054894 (18l) which has advanced to clinical trials as a first in class approach targeting the receptor.
- 9 July 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (8) , 1662-1669
Peptidylarginine Deiminase (PAD) Inhibitor Optimization through Displacement of a Trapped Water Molecule
Excess protein citrullination, a post-translational modification converting arginine to citrulline, has been associated with a range of autoimmune and neurological disorders, as well as cancers. Protein citrullination is mediated by the peptidylarginine deiminase enzyme family (PAD1-4), and inhibition of one or several PAD isozymes in combination may offer a therapeutic approach to targeting these diseases. Building upon the discovery of PAD-PF2, an allosteric inhibitor of PAD1-4, herein, we report on the optimization of potency and pharmacokinetic properties while minimizing hERG channel liabilities within this novel chemical series. Through structure-based ligand design, a structural water was successfully displaced, allowing expansion of the ligand binding site and access to a previously unexplored hydrophobic pocket resulting in a 10-fold improvement in potency. Compound 4f demonstrated potent inhibition of PAD-mediated citrullination in human and rat neutrophils, reduced hERG channel liabilities, and good oral bioavailability in preclinical animal species.
- 9 July 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (8) , 1662-1669
Peptidylarginine Deiminase (PAD) Inhibitor Optimization through Displacement of a Trapped Water Molecule
Excess protein citrullination, a post-translational modification converting arginine to citrulline, has been associated with a range of autoimmune and neurological disorders, as well as cancers. Protein citrullination is mediated by the peptidylarginine deiminase enzyme family (PAD1-4), and inhibition of one or several PAD isozymes in combination may offer a therapeutic approach to targeting these diseases. Building upon the discovery of PAD-PF2, an allosteric inhibitor of PAD1-4, herein, we report on the optimization of potency and pharmacokinetic properties while minimizing hERG channel liabilities within this novel chemical series. Through structure-based ligand design, a structural water was successfully displaced, allowing expansion of the ligand binding site and access to a previously unexplored hydrophobic pocket resulting in a 10-fold improvement in potency. Compound 4f demonstrated potent inhibition of PAD-mediated citrullination in human and rat neutrophils, reduced hERG channel liabilities, and good oral bioavailability in preclinical animal species.
- Open Access
- 22 January 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Oxygen Migration into Carbon–Carbon Single Bonds by Photochemical Oxidation
The editing of organic molecules through single-atom modifications is an enabling capability for medicinal chemistry. While several examples of single-atom insertions into the carbon–carbon double bonds of unsaturated aromatic ring systems have been reported, heteroatom insertions into chemically inert carbon–carbon single bonds are comparatively rare. We report herein a photochemical strategy for formal migration of oxygen atoms into carbon–carbon single bonds. This protocol is based on the ability of copper(II) salts to induce photochemical homolytic cleavage of carbon–carbon bonds adjacent to alcohols and to mediate oxidative coupling reactions of the resulting organoradical intermediates. Application of this method to cyclic alcohol substrates results in oxygen-atom insertions into saturated carbocyclic rings, and its extension to linear alcohol substrates enables atomic permutation of hydroxymethyl functionalities into methyl ethers.
- 22 January 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessOxygen Migration into Carbon–Carbon Single Bonds by Photochemical Oxidation
The editing of organic molecules through single-atom modifications is an enabling capability for medicinal chemistry. While several examples of single-atom insertions into the carbon–carbon double bonds of unsaturated aromatic ring systems have been reported, heteroatom insertions into chemically inert carbon–carbon single bonds are comparatively rare. We report herein a photochemical strategy for formal migration of oxygen atoms into carbon–carbon single bonds. This protocol is based on the ability of copper(II) salts to induce photochemical homolytic cleavage of carbon–carbon bonds adjacent to alcohols and to mediate oxidative coupling reactions of the resulting organoradical intermediates. Application of this method to cyclic alcohol substrates results in oxygen-atom insertions into saturated carbocyclic rings, and its extension to linear alcohol substrates enables atomic permutation of hydroxymethyl functionalities into methyl ethers.
- Open Access
- 27 September 2023
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 14 (40) , 10994-10996
A focus on computer vision for non-contact monitoring of catalyst degradation and product formation kinetics
Chemists know the value of looking at a reaction for clues about reaction progress and success, but what-it-looks-like has never been quantified. Reid and co-workers (C. Yan, M. Cowie, C. Howcutt, K. M. P. Wheelhouse, N. S. Hodnett, M. Kollie, M. Gildea, M. H. Goodfellow and M. Reid, Chem. Sci., 2023, 14, 5323–5331, https://doi.org/10.1039/d2sc05702f) have developed an approach that uses camera footage of reactions to obtain quantitative descriptors of changes in reaction mixtures to support kinetic analysis.
- 27 September 2023
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 14 (40) , 10994-10996
Open AccessA focus on computer vision for non-contact monitoring of catalyst degradation and product formation kinetics
Chemists know the value of looking at a reaction for clues about reaction progress and success, but what-it-looks-like has never been quantified. Reid and co-workers (C. Yan, M. Cowie, C. Howcutt, K. M. P. Wheelhouse, N. S. Hodnett, M. Kollie, M. Gildea, M. H. Goodfellow and M. Reid, Chem. Sci., 2023, 14, 5323–5331, https://doi.org/10.1039/d2sc05702f) have developed an approach that uses camera footage of reactions to obtain quantitative descriptors of changes in reaction mixtures to support kinetic analysis.
- 26 September 2023
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 88 (19) , 13727-13740
Convergent Syntheses of Isomeric Imidazolospiroketones as Templates for Acetyl-CoA Carboxylase (ACC) Inhibitors
The synthesis of imidazole fused spirocyclic ketones as templates for acetyl-CoA carboxylase (ACC) inhibitors is reported. By completing the spirocyclic ring closure via divergent pathways, the synthesis of these regioisomers from common intermediates was developed. Through an aldehyde homologation/ transmetalation strategy, one isomer was formed selectively. The second desired isomer was obtained via an intramolecular aromatic homolytic substitution reaction. Preparation of these isomeric spiroketones provided templates which, upon elaboration, led to key structure-activity relationship (SAR) points for delivery of potent ACC inhibitors.
- 26 September 2023
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 88 (19) , 13727-13740
Convergent Syntheses of Isomeric Imidazolospiroketones as Templates for Acetyl-CoA Carboxylase (ACC) Inhibitors
The synthesis of imidazole fused spirocyclic ketones as templates for acetyl-CoA carboxylase (ACC) inhibitors is reported. By completing the spirocyclic ring closure via divergent pathways, the synthesis of these regioisomers from common intermediates was developed. Through an aldehyde homologation/ transmetalation strategy, one isomer was formed selectively. The second desired isomer was obtained via an intramolecular aromatic homolytic substitution reaction. Preparation of these isomeric spiroketones provided templates which, upon elaboration, led to key structure-activity relationship (SAR) points for delivery of potent ACC inhibitors.
- 15 August 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 94, 129454
6-Azaspiro[2.5]octanes as small molecule agonists of the human glucagon-like peptide-1 receptor
- 15 August 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 94, 129454
6-Azaspiro[2.5]octanes as small molecule agonists of the human glucagon-like peptide-1 receptor